Weekly ReportMar 17–23, 2026
Sepsis, week 12 edition
We read 148 papers and selected 3.
Summary
This week’s sepsis literature highlights advances in precision immunophenotyping, host susceptibility mechanisms, and innate-immune regulation. A validated three-biomarker ML score (procalcitonin, sTREM-1, IL-6) accurately quantifies immune dysregulation and identifies patients who benefit from hydrocortisone. Mechanistic studies reveal host genetic/metabolic axes (ERβ–Stoml2 acetylation) and a glycosylation regulator (CLSTN3) that tune TLR-driven inflammation, offering druggable targets. These findings converge toward biologically stratified immunomodulation and new translational targets for sepsis.
Selected Articles
1. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
The authors derived and externally validated a parsimonious three-biomarker ML framework (procalcitonin, soluble TREM-1, IL-6) that reproduces an immune dysregulation continuum (DIP/cDIP) originally defined by 35 biomarkers. The 3-marker model predicted dysregulation with high accuracy across five external cohorts and showed that only severely dysregulated patients derived a survival benefit from hydrocortisone in a post-hoc RCT reanalysis.
Impact: Provides a validated, pragmatic biomarker tool that operationalizes immune-status measurement and identifies patients likely to benefit from immunomodulation, enabling precision trial design and potential bedside stratification.
Clinical Implications: Incorporate PCT, sTREM-1, and IL-6-based scoring to stratify patients for immunomodulatory therapies (eg, hydrocortisone) and enrich trials for likely responders; requires assay availability and prospective validation in sepsis-specific RCTs.
Key Findings
- Derived DIP stages and a continuous cDIP score from 35 biomarkers and reduced to a 3-biomarker predictive model with 91.2% accuracy for DIP stage.
- cDIP increases independently associated with higher mortality (OR 1.26 per 10% increase) and secondary infections.
- Post-hoc RCT reanalysis showed hydrocortisone reduced 30-day mortality only in severely dysregulated patients (DIP3 or cDIP ≥0.63).
2. Estrogen receptor β deficiency increases susceptibility to sepsis through metabolic reprogramming-induced macrophage pyroptosis.
This study shows reduced ERβ expression in sepsis patients and demonstrates that ERβ deficiency drives fatty-acid-oxidation–linked increases in acetyl-CoA and Stoml2 K221 acetylation, causing mitochondrial dysfunction and macrophage pyroptosis. Genetic mutation of Stoml2 K221 rescued mitochondrial function and improved survival in septic mice, linking a host genetic/metabolic axis to sepsis susceptibility and suggesting actionable targets.
Impact: Identifies a concrete, mechanistic ERβ–immunometabolism–pyroptosis axis with in vivo rescue, providing biomarker and therapeutic leads (ERβ modulation, FAO/acetylation inhibitors) for personalized sepsis interventions.
Clinical Implications: Assess ERβ expression as a susceptibility or prognostic biomarker and prioritize translational work on selective ERβ modulators or FAO/acetylation pathway inhibitors to prevent macrophage pyroptosis in high-risk patients.
Key Findings
- ERβ expression is reduced in peripheral blood of sepsis patients and inversely correlates with severity.
- ERβ deficiency increases FAO, acetyl-CoA, and Stoml2 K221 acetylation, leading to mitochondrial dysfunction and macrophage pyroptosis.
- Mutating Stoml2 K221 mitigates pyroptosis and improves survival in septic mice.
3. Calsyntenin-3 suppresses inflammation via inhibition of TLR N-glycosylation and membrane localization.
A genome-wide CRISPR screen identified CLSTN3 as an endogenous inhibitor of TLR-driven inflammation. CLSTN3 binds DDOST, disrupts DDOST–STT3A interaction, impairs OST assembly, and reduces N-glycosylation and membrane translocation of TLR4 (and other TLRs), broadly dampening innate signaling — revealing TLR glycosylation as a modifiable control point.
Impact: Mechanistically uncovers N-glycosylation control of TLR trafficking as a regulator of innate inflammatory output and nominates the CLSTN3–OST axis as a novel, potentially druggable anti-inflammatory target relevant to sepsis pathophysiology.
Clinical Implications: Develop therapeutics that modulate TLR N-glycosylation or mimic CLSTN3 function to temper excessive innate activation in sepsis; requires in vivo sepsis-model validation and careful safety assessment due to potential effects on proteostasis.
Key Findings
- Genome-wide CRISPR screen identified CLSTN3 as a suppressor of TLR4-triggered inflammation in macrophages.
- CLSTN3 binds DDOST and impairs DDOST–STT3A interaction, reducing OST complex assembly and TLR N-glycosylation.
- Reduced N-glycosylation limits membrane localization and activation of TLR4 (and TLR3/7/9), broadly dampening innate signaling.